1. Home
  2. RBC vs RPRX Comparison

RBC vs RPRX Comparison

Compare RBC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RBC Bearings Incorporated

RBC

RBC Bearings Incorporated

HOLD

Current Price

$559.18

Market Cap

17.5B

Sector

Industrials

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$45.12

Market Cap

19.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBC
RPRX
Founded
1919
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.5B
19.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RBC
RPRX
Price
$559.18
$45.12
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$495.83
$47.75
AVG Volume (30 Days)
206.9K
3.6M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
2.08%
EPS Growth
N/A
N/A
EPS
N/A
1.78
Revenue
N/A
$2,378,193,000.00
Revenue This Year
$14.83
$39.10
Revenue Next Year
$12.08
$5.02
P/E Ratio
$64.90
$25.38
Revenue Growth
N/A
5.06
52 Week Low
$297.28
$29.66
52 Week High
$564.70
$46.14

Technical Indicators

Market Signals
Indicator
RBC
RPRX
Relative Strength Index (RSI) 77.95 68.51
Support Level $545.51 $42.50
Resistance Level $564.70 $46.14
Average True Range (ATR) 13.95 0.96
MACD 0.05 0.06
Stochastic Oscillator 80.62 71.52

Price Performance

Historical Comparison
RBC
RPRX

About RBC RBC Bearings Incorporated

RBC Bearings Inc is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: Industrial, which derives maximum revenue, and Aerospace/Defense. The Aerospace/Defense segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the Industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: